Grifols (NASDAQ:GRFS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Friday.
Separately, Morgan Stanley initiated coverage on shares of Grifols in a research report on Wednesday, February 12th. They issued an "overweight" rating on the stock.
Check Out Our Latest Analysis on GRFS
Grifols Stock Down 0.6%
NASDAQ GRFS traded down $0.05 during trading on Friday, hitting $8.18. The stock had a trading volume of 680,695 shares, compared to its average volume of 1,159,610. Grifols has a 12 month low of $5.79 and a 12 month high of $9.96. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The company's 50-day moving average price is $7.32 and its two-hundred day moving average price is $7.58. The company has a market capitalization of $5.62 billion, a PE ratio of 6.99 and a beta of 0.44.
Hedge Funds Weigh In On Grifols
Several hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its position in Grifols by 1.9% during the first quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company's stock valued at $29,948,000 after purchasing an additional 80,507 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Grifols during the 1st quarter worth approximately $184,000. Royal Bank of Canada boosted its holdings in shares of Grifols by 21.7% in the 1st quarter. Royal Bank of Canada now owns 486,824 shares of the biotechnology company's stock valued at $3,461,000 after buying an additional 86,768 shares during the last quarter. Vident Advisory LLC grew its stake in shares of Grifols by 134.5% in the first quarter. Vident Advisory LLC now owns 69,564 shares of the biotechnology company's stock valued at $495,000 after buying an additional 39,902 shares in the last quarter. Finally, Groupe la Francaise acquired a new position in Grifols during the first quarter worth $1,699,000.
About Grifols
(
Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Recommended Stories
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
